Your browser doesn't support javascript.
loading
Correction to: Prevalence of tumour-infiltrating CD103+ cells identifies therapeutic-sensitive prostate cancer with poor clinical outcome.
Zhou, Quan; Ou, Yuxi; Dai, Xiyu; Chen, Xinan; Wu, Siqi; Chen, Wensun; Hu, Mengbo; Yang, Chen; Zhang, Limin; Jiang, Haowen.
Afiliação
  • Zhou Q; Department of Urology, Huashan Hospital, Fudan University, Shanghai, China.
  • Ou Y; Fudan Institute of Urology, Huashan Hospital, Fudan University, Shanghai, China.
  • Dai X; Department of Urology, Huashan Hospital, Fudan University, Shanghai, China.
  • Chen X; Fudan Institute of Urology, Huashan Hospital, Fudan University, Shanghai, China.
  • Wu S; Department of Urology, Huashan Hospital, Fudan University, Shanghai, China.
  • Chen W; Fudan Institute of Urology, Huashan Hospital, Fudan University, Shanghai, China.
  • Hu M; Department of Urology, Huashan Hospital, Fudan University, Shanghai, China.
  • Yang C; Fudan Institute of Urology, Huashan Hospital, Fudan University, Shanghai, China.
  • Zhang L; Department of Urology, Huashan Hospital, Fudan University, Shanghai, China.
  • Jiang H; Fudan Institute of Urology, Huashan Hospital, Fudan University, Shanghai, China.
Br J Cancer ; 128(9): 1788-1789, 2023 May.
Article em En | MEDLINE | ID: mdl-36941407
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies / Prevalence_studies / Risk_factors_studies Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies / Prevalence_studies / Risk_factors_studies Idioma: En Ano de publicação: 2023 Tipo de documento: Article